- Fang G-D, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990; 69: 307–16.
- Harrison BDW, Farr BM, Pugh S, Selkon JB. Community-acquired pneumonia in adults in British hospitals in 1982–1983: A survey of aetiology, mortality, prognostic factors and outcome. Quarterly J Med, New Series 1987; 62: 195–220.
- Örtqvist Å, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Resp J 1990; 3: 1105–13.
- Powers DC, Anderson EL, Lottenbach K, Mink CM. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Inf Dis 1996; 173: 1014–8.
- Watson DA, Kapur V, Musher DM, Jacobson JW, Musser JM. Identification, cloning, and sequencing of DNA essential for encapsulation of Streptococcus pneumoniae. Curr Microbiol 1995; 31: 251–9.
- Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995; 33: 2759–62.
- Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity and treatment. Clin Infect Dis 1992; 14: 801–9.
- Robbins JB, Austrian R, Lee C-J, et al. Considerations for formulating the second generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types. J Infect Dis 1983; 148: 1136–59.
- Jorgensen JH, Howell AW, Maher LA, Facklam RR. Serotypes of respiratory isolates of Streptococcus pneumoniae compared with the capsular types included in the current pneumococcal vaccine. J Infect Dis 1991; 163: 644–6.
- Fedson DS, Baldwin JA. Previous hospital care as a risk factor for pneumonia. JAMA 1982; 248: 1989–95.
- Fedson DS, Harward MP, Reid RA, Kaiser DL. Hospital-based pneumococcal immunization. JAMA 1990; 264: 1117–22.
- Hedlund JU, Örtqvist ÅB, Kalin M, Scalia-Tomba G, Giesecke J. Risk of pneumonia in patients previously treated in hospital for pneumonia. Lancet 1992; 340: 396–7.
- Örtqvist Å, Hedlund J, Burman L-Å, et al. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998; 351: 399–403.
- Kalin M, Lindberg AA, Tunevall G. Etiological diagnosis of bacterial pneumonia by Gram stain and quantitative culture of expectorates. Scand J Infect Dis 1983; 15: 153–60.
- Jalonen E, Paton JC, Koskela M, Kerttula Y, Leinonen M. Measurements of antibody responses to pneumolysin: a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect Dis 1989; 19: 127–34.
- Leinonen M, Syrjälä H, Jalonen E, Kujala P, Herva E. Demonstration of pneumolysin antibodies in circulating immune complexes – a new diagnostic method for pneumococcal pneumonia. Serodiagn Immunother Infect Dis 1990; 4: 451–8.
- Konradsen HB, Skov Sörensen UB, Henrichsen J. A modified enzyme-linked immunosorbent assay for measuring type-specific anti-pneumococcal capsular polysaccharide antibodies. J Immunol Methods 1993; 164: 13–20.
- Quataert SA, Kirch CS, Quackenbush Wiedl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, Lot 89-S. Clin Diagn Lab Immunol 1995; 2: 590–7.
- Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453–60.
- Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89: 184–94.
- Rubins JB, Puri AKG, Loch J, et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 1998; 178: 431–40.
- Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine related immunity to Streptococcus pneumoniae. J Infect Dis 1986; 154: 245–56.
- Hedlund JU, Kalin ME, Ortqvist Ab, Henrichsen J. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med 1994; 154: 1961–5.
- Ruben FL, Uhrin M. Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine. J Infect Dis 1985; 151: 845–9.
- Amman AJ, Schiffman G, Austrian R. The antibody responses to pneumooccal capsular polysaccharides in aged individuals. Proc Soc Exp Biol Med 1980; 164: 312–6.
- Musher DM, Groover JE, Graviss EA, Baughn RE. The lack of association between aging and postvaccin levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Clin Infect Dis 1996; 22: 165–7.
- Roghmann KJ, Tabloski PA, Bentley DW, Schiffman GS. Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment. J Gerontol 1987; 42: 265–70.
- Musher DM, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990; 161: 728–35.
- Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996; 173: 387–93.
- Landesman SH, Schiffman G. Assesment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis 1981; 3 Suppl: S71–81.
- Schiffman G, Douglas RM, Bonner MJ, Robbins M, Austrian R. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods 1980; 33: 133–44.
- Musher DM, Watson DA, Baughn RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis 1990; 161: 736–40.
- Musher DM, Watson DA, Dominguez EA. Pneumococcal vaccination: work to date and future prospects. Am J Med Sci 1990; 300: 45–52.
- Hosmer DW, Lemeshow S. Applied Logistic Regression. John Wiley & Sons, 1989.
- Sisk J, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333–9.
- Macfarlane JT. Hospital study of adult community-acquired pneumonia. Lancet 1982; 2: 255–8.
- Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989; 11: 586–99.
- Kerttula Y, Leinonen M, Koskela M, Mäkelä PH. The aetiology of pneumonia. Application of bacterial serology and basic laboratory methods. J Infect 1987; 14: 21–30.
- Farr BM, Kaiser DL, Harrison BDW, Conolly CK. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 1989; 44: 1031–5.
- Dintzis RZ. Rational design of conjugate vaccines. Pediatric Res 1992; 32: 376–85.
- Åhman H, Käyhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998; 17: 211–6.
- Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101: 604–11.
- Molrine DC, George S, Tarbell N, et al. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin Disease. Ann Intern Med 1995; 123: 828–34.
- Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharides pneumococcal vaccine after treatment of Hodgkin’s Disease. J Infect Dis 1996; 173: 256–8.
- Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996; 173: 83–90.
Scandinavian Journal of Infectious Diseases
Volume 32, 2000 - Issue 3